Australia's national prion disease surveillance body received 84 initial case notifications during 2025, and at 31 December 2025 more than half of them (44) remained classified as 'incomplete', according to the annual report of the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR), published on 21 July 2026 in the Australian government journal Communicable Diseases Intelligence (doi 10.33321/cdi.2026.50.050). Of the remainder, 35 cases had been confirmed as 'definite' or 'probable' prion disease and five had been excluded. The report, by Christiane Stehmann, Steven Collins and colleagues at the Florey Institute and the University of Melbourne, also records 788 domestic cerebrospinal fluid specimens referred for diagnostic testing during the year, and 92 people with suspected human prion disease formally added to the national register.
This is a surveillance report, not a study of a treatment: it describes case ascertainment and classification, not outcomes for any individual. The ANCJDR conducts nationwide surveillance of Creutzfeldt-Jakob disease and other human prion diseases, covering the period since 1 January 1970 with prospective surveillance since 1 October 1993, and has offered diagnostic CSF 14-3-3 protein testing in Australia since September 1997. The registry reports that no cases of variant CJD or iatrogenic CJD were identified in Australia during 2025, and that 56 per cent of suspected prion-disease-related deaths that year underwent neuropathological examination.
The unclassified backlog is not new, and it is not evidence that cases are being missed. The registry's previous report, published on 22 October 2025 and covering 2024, recorded 83 initial case notifications for that year, of which 42 were still 'incomplete' at 31 December 2024, with 21 classified as 'definite', 17 as 'probable' and three excluded through neuropathological examination. Classification depends on information that arrives after notification: clinical follow-up, investigations, and in many cases post-mortem examination of brain tissue, which is the only route to a 'definite' designation.
For families, the practical meaning is that a year-end figure is a snapshot of an open process rather than a final tally. Sporadic CJD typically progresses over months, and the paperwork that confirms it often closes after the person has died. Anyone with questions about a notification, a test result or a classification should raise them with the treating clinician or the registry, not read them off a national table.